Julia A. Beaver
271 works · 11,018 citations · h-index 59
Top works
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
- Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
- “Dangling” Accelerated Approvals in Oncology
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
- The On- and Off-Ramps of Oncology Accelerated Approval
- Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials
- Trends in the approval of cancer therapies by the FDA in the twenty-first century
- FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
- Metastasis-free Survival — A New End Point in Prostate Cancer Trials
- FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
- External control arms in oncology: current use and future directions
- FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
- FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer